American Bio Medica Corporation
ABMC · OTC
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $164 | $167 | $209 | $185 |
| % Growth | -1.8% | -20.1% | 13% | – |
| Cost of Goods Sold | $90 | $307 | $218 | $258 |
| Gross Profit | $74 | -$140 | -$9 | -$73 |
| % Margin | 45.1% | -83.8% | -4.3% | -39.5% |
| R&D Expenses | $28 | $22 | $22 | $18 |
| G&A Expenses | $238 | $202 | $205 | $215 |
| SG&A Expenses | $258 | $230 | $231 | $256 |
| Sales & Mktg Exp. | $20 | $28 | $26 | $41 |
| Other Operating Expenses | $0 | $850 | $1 | $1 |
| Operating Expenses | $286 | $1,102 | $253 | $274 |
| Operating Income | -$212 | -$1,242 | -$262 | -$347 |
| % Margin | -129.3% | -743.7% | -125.4% | -187.6% |
| Other Income/Exp. Net | $2,093 | $925 | -$52 | -$51 |
| Pre-Tax Income | $1,881 | -$317 | -$314 | -$398 |
| Tax Expense | $0 | $0 | $0 | $2 |
| Net Income | $3,953 | -$317 | -$366 | -$400 |
| % Margin | 2,410.4% | -189.8% | -175.1% | -216.2% |
| EPS | 0.082 | -0.007 | -0.008 | -0.008 |
| % Growth | 1,345.5% | 13.2% | 8.4% | – |
| EPS Diluted | 0.082 | -0.007 | -0.008 | -0.008 |
| Weighted Avg Shares Out | 48,098 | 48,058 | 48,098 | 48,098 |
| Weighted Avg Shares Out Dil | 48,098 | 48,058 | 48,098 | 48,098 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $3 | $0 | $0 |
| Interest Expense | $21 | $41 | $53 | $52 |
| Depreciation & Amortization | $8 | $13 | $12 | $13 |
| EBITDA | $1,910 | -$263 | -$249 | -$333 |
| % Margin | 1,164.6% | -157.5% | -119.1% | -180% |